Cargando…

Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004–2014

Detalles Bibliográficos
Autores principales:	D’Souza, Anita, Zhang, Mei-Jie, Huang, Jiaxing, Fei, Mingwei, Pasquini, Marcelo, Hamadani, Mehdi, Hari, Parameswaran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587375/ https://www.ncbi.nlm.nih.gov/pubmed/28663578 http://dx.doi.org/10.1038/leu.2017.185

Ejemplares similares

Prevalence and Significance of Sarcopenia in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation
por: Williams, Alexis, et al.
Publicado: (2020)

Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: A Center for International Blood and Marrow Transplant Research Analysis
por: Mahindra, Anuj, et al.
Publicado: (2017)

Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation
por: Uy, Geoffrey L., et al.
Publicado: (2015)

Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
por: Dhakal, Binod, et al.
Publicado: (2019)

Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma
por: Maffini, Enrico, et al.
Publicado: (2019)

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy
por: Dhakal, Binod, et al.
Publicado: (2021)

Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma
por: Kansagra, Ankit, et al.
Publicado: (2022)

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Rodriguez, Tulio E., et al.
Publicado: (2016)

Early Relapse after Autologous Hematopoietic Cell Transplantation remains a Poor Prognostic Factor in Multiple Myeloma but Outcomes Have Improved Over Time
por: Kumar, Shaji K, et al.
Publicado: (2017)

Outcomes of Salvage Autologous Versus Allogeneic Hematopoietic Cell Transplantation for Relapsed Multiple Myeloma After Initial Autologous Hematopoietic Cell Transplantation
por: Wirk, Baldeep, et al.
Publicado: (2013)

Sequential, Autologous Hematopoietic Stem Cell Transplant Followed by Renal Transplant in Multiple Myeloma
por: Bhowmik, D., et al.
Publicado: (2017)

Pulmonary Lymphangitic Spread of Multiple Myeloma as Early Relapse after Autologous Stem Cell Transplantation
por: Thapa, Bicky, et al.
Publicado: (2021)

Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
por: Kharfan-Dabaja, Mohamed A, et al.
Publicado: (2013)

Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma without Cryopreservation
por: Al-Anazi, Khalid Ahmed
Publicado: (2012)

Update on the Role of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Tosi, P., et al.
Publicado: (2012)

Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation
por: Jantunen, Esa, et al.
Publicado: (2023)

Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis
por: D'Souza, Anita, et al.
Publicado: (2017)

Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Tuchman, S. A., et al.
Publicado: (2012)

Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients
por: FU, CHENGCHENG, et al.
Publicado: (2013)

Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia
por: Eapen, Mary, et al.
Publicado: (2020)

Tandem Autologous Hematopoietic Stem Cell Transplantation in Very Young Patients with Multiple Myeloma
por: Naithani, Rahul, et al.
Publicado: (2020)

Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis
por: Hamadani, Mehdi, et al.
Publicado: (2020)

Trends in utilization of stored cryopreserved autologous peripheral hematopoietic cells intended for a second (or beyond) autologous hematopoietic cell transplantation in patients with multiple myeloma: a single center experience
por: Yassine, Farah, et al.
Publicado: (2023)

SECOND TRANSPLANTS FOR MULTIPLE MYELOMA RELAPSING AFTER A PRIOR AUTOTRANSPLANT – REDUCED INTENSITY ALLOGENEIC VERSUS AUTOLOGOUS TRANSPLANTATION
por: Freytes, Cesar O., et al.
Publicado: (2013)

Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma
por: Cox, J E, et al.
Publicado: (2014)

Membranous Glomerulopathy After Autologous Hematopoietic Stem Cell Transplant in a Patient With Multiple Myeloma
por: Rodríguez Feria, Daniela, et al.
Publicado: (2021)

Controversies and Recent Advances in Hematopoietic Cell Transplantation for Follicular Non-Hodgkin Lymphoma
por: Kanate, Abraham S., et al.
Publicado: (2012)

Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis
por: Hamadani, Mehdi, et al.
Publicado: (2022)

Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation
por: Knight, Jennifer M., et al.
Publicado: (2018)

Management of central nervous system involvement in multiple myeloma after autologous hematopoietic stem cell transplantation
por: Mousavi-Fatemi, Khatereh, et al.
Publicado: (2020)

Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients
por: Rosenberg, A. S., et al.
Publicado: (2021)

Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after three or more lines of prior therapy: evidence of durable benefit
por: Mei, Matthew, et al.
Publicado: (2022)

Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT
por: Drozd-Sokołowska, Joanna, et al.
Publicado: (2022)

Autologous hematopoietic transplantation following COVID‐19 infection
por: Brzycki, Marthilde, et al.
Publicado: (2021)

Autologous transplant for myeloma: when the old meets the new
por: Gay, Francesca, et al.
Publicado: (2017)

Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
por: Minnie, Simone A., et al.
Publicado: (2021)

Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma
por: Green, Damian J., et al.
Publicado: (2016)

Autologous Graft-Versus-Host Disease of the Gastrointestinal Tract in Patients With Multiple Myeloma and Hematopoietic Stem Cell Transplantation
por: Hammami, Muhammad B., et al.
Publicado: (2018)

PB2007: FACTORS ASSOCIATED WITH EARLY RELAPSE IN MYELOMA PATIENTS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Karatas, A., et al.
Publicado: (2022)

Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_87g8sab4v3iojs5tu37554iq1o